Business

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

CHICAGO, IL / ACCESSWIRE / July 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global

articleCosmos Health Inc.July 18, 20245/company/cosmos-health-inc/news/cosmos-healths-cana-secures-additional-contract-manufacturing-agreement-with-provident-pharmaceuticals-for-700000-units-bringing-total-order-book-to-502-million-units
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

About this update from Cosmos Health Inc.

[{"type":"text","content":"CHICAGO, IL / ACCESSWIRE / July 18, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ('Cana'), has secured additional contract manufacturing agreements with Provident Pharmaceuticals ('Provident'), a specialty pharmaceutical company established in 2012 focused on commercializing and marketing niche and legacy pharmaceutical products, as well as medical devices in specific therapeutic areas.Specifically, Cana secured additional orders to manufacture the following medicines:408,000 units of MIOREL, used to reduce and relieve excessive muscle spasms, commonly seen in conditions like multiple sclerosis, diseases, or spinal cord injuries;222,000 units of CALCIFOLIN, an active metabolite of folic acid necessary for nucleic acid synthesis during cytotoxic therapy;72,000 units of DEXA-DOSE, a synthetic glucocorticoid with potent anti-inflammatory properties, also used for its anti-allergic, anti-toxic, antipyretic, and immunosuppressive effects.Moreover, as previously announced on July 3, 2024, Cana secured another contract with Provident to manufacture 4.32 million units (vials) of DE3-SOLE, which treats vitamin D deficiency by aiding calcium absorption and promoting overall health, bringing the total order book with Provident to 5.02 million units.Greg Siokas, CEO of Cosmos Health, stated: \"We are accelerating the scaling up of Cana's contract manufacturing division. These additional orders from Provident attest to our capabilities, and we eagerly anticipate securing further contracts that will deliver stable, high-margin cash flows for Cosmos.\"About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency...

More updates from Cosmos Health Inc.